Vistagen Therapeutics annual net profit margin
2011
2012
2013
2017
2021
2022
2024
2025
2026
Vistagen Therapeutics Net Profit Margin Growth & History (VTGN)
Vistagen Therapeutics's net profit margin was −5,491.33% for fiscal 2026.
View full Vistagen Therapeutics company overviewVistagen Therapeutics annual net profit margin history
| Fiscal year | Period ended | Net profit margin | Change (percentage points) |
|---|---|---|---|
| 2026 | 2026-03-31 | −5,491.33% | +5088.50 pp |
| 2025 | 2025-03-31 | −10,579.84% | −7820.25 pp |
| 2024 | 2024-03-31 | −2,759.59% | — |
| 2022 | 2022-03-31 | −4,307.19% | −2661.09 pp |
| 2021 | 2021-03-31 | −1,646.09% | — |
| 2017 | 2017-03-31 | −820.44% | — |
| 2013 | 2013-03-31 | −6,430.49% | −5520.83 pp |
| 2012 | 2012-03-31 | −909.66% | −451.81 pp |
| 2011 | 2011-03-31 | −457.86% | — |
Vistagen Therapeutics quarterly net profit margin
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q3.17
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q1.26
Q2.26
Q3.26
Q4.26
Q1.27
| Fiscal quarter | Period ended | Net profit margin | Change (percentage points) |
|---|---|---|---|
| Q1 2027 | 2026-06-30 | −882.79% | +5303.68 pp |
| Q4 2026 | 2026-03-31 | −3,507.33% | — |
| Q3 2026 | 2025-12-31 | −6,237.29% | −216.35 pp |
| Q2 2026 | 2025-09-30 | −7,525.97% | −443.46 pp |
| Q1 2026 | 2025-06-30 | −6,186.48% | +6590.91 pp |
| Q3 2025 | 2024-12-31 | −6,020.94% | −4475.93 pp |
| Q2 2025 | 2024-09-30 | −7,082.51% | −4712.73 pp |
| Q1 2025 | 2024-06-30 | −12,777.38% | −8877.38 pp |
| Q4 2024 | 2024-03-31 | −4,808.59% | +2138.57 pp |
| Q3 2024 | 2023-12-31 | −1,545.01% | +3877.88 pp |
| Q2 2024 | 2023-09-30 | −2,369.78% | — |
| Q1 2024 | 2023-06-30 | −3,900.00% | +2477.39 pp |
| Q4 2023 | 2023-03-31 | −6,947.16% | +35842.58 pp |
| Q3 2023 | 2022-12-31 | −5,422.89% | −2479.61 pp |
| Q1 2023 | 2022-06-30 | −6,377.39% | −4190.16 pp |
| Q4 2022 | 2022-03-31 | −42,789.74% | −41384.54 pp |
| Q3 2022 | 2021-12-31 | −2,943.28% | −1253.64 pp |
| Q2 2022 | 2021-09-30 | −3,574.02% | −2586.66 pp |
| Q1 2022 | 2021-06-30 | −2,187.24% | — |
| Q4 2021 | 2021-03-31 | −1,405.20% | — |
| Q3 2021 | 2020-12-31 | −1,689.64% | — |
| Q2 2021 | 2020-09-30 | −987.37% | — |
| Q3 2017 | 2016-12-31 | −211.04% | — |
| Q1 2013 | 2012-06-30 | −911.18% | −476.76 pp |
| Q4 2012 | 2012-03-31 | −648.83% | +353.73 pp |
| Q3 2012 | 2011-12-31 | −225,000.00% | −224419.85 pp |
| Q2 2012 | 2011-09-30 | −713.92% | −320.58 pp |
| Q1 2012 | 2011-06-30 | −434.41% | −300.66 pp |
| Q4 2011 | 2011-03-31 | −1,002.55% | — |
| Q3 2011 | 2010-12-31 | −580.15% | — |
| Q2 2011 | 2010-09-30 | −393.34% | — |
| Q1 2011 | 2010-06-30 | −133.75% | — |
Vistagen Therapeutics net profit margin trends
Over the last five fiscal years, Vistagen Therapeutics's net profit margin decreased from −1,646.09% to −5,491.33%, a change of −3845.24 percentage points. The latest reported quarter, Q1 2027, shows −882.79%.
About the metric
What net profit margin means
Net profit margin measures the percentage of revenue remaining as net income after operating costs, interest, taxes, and other expenses. It shows how much bottom-line profit or loss a company generates from each dollar of revenue.
Calculation and source
How net profit margin is calculated
TickerStat calculates net profit margin as SEC-reported net income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Vistagen Therapeutics source filings ↗